Skip to main content
    • Aa
    • Aa

Time to full publication of studies of anticancer drugs for breast cancer, and the potential for publication bias

  • Petra Harris (a1), Andrea Takeda (a1), Emma Loveman (a1) and Debbie Hartwell (a1)

Objectives: Nonpublication of results of clinical trials can contribute to inappropriate medical decisions. The primary aim of this systematic review was to investigate publication delays between conference abstracts and full journal publications from randomized controlled trial results of new anticancer agents for breast cancer. The review was restricted to anticancer agents previously, or due to be, appraised in the United Kingdom by the National Institute for Health and Clinical Excellence. A secondary objective was to identify whether there are any apparent biases in the publication and reporting of these trials.

Methods: We searched six electronic databases up to August 2007, including Medline and the Cochrane Library. Two reviewers independently selected studies, extracted and assessed the data.

Results: Six anticancer treatments were identified: docetaxel, paclitaxel, trastuzumab, gemcitabine, lapatinib, and bevacizumab. Of eighteen included trials, only four publications from three trials reported the same outcomes in both abstract and full publication. Time delays ranged from 5 to 19 months. Eleven trial abstracts were still without a full publication at the end of our searches, varying from 3 to 38 months since abstract publication. Observational analysis revealed no particular publishing biases.

Conclusions: Whereas delays in publication appear reasonable over a period of months, many were not published in full over a period of years and others would appear to be unlikely to ever be published. Further research should investigate the impact of publication delays on the availability of new drug treatments in clinical practice.

Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

1.S Al-Marzouki , I Roberts , T Marshall , The effect of scientific misconduct on the results of clinical trials: A Delphi survey. Contemp Clin Trials. 2005;26:331337.

6.J Carmichael . Current issues in cancer: Cancer chemotherapy: Identifying novel anticancer drugs. BMJ. 1994;308:12881290.

8.I Chalmers . Underreporting research is scientific misconduct. JAMA. 1990;263:14051408.

9.K Dickersin , CM Olson , D Rennie , Association between time interval to publication and statistical significance. JAMA. 2002;287:28292831.

10.CE Geyer , J Forster , D Lindquist , Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:27332743.

13. I Henderson , D Berry , G Demetri , Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node positive primary breast cancer. J Clin Oncol. 2003;21:976983.

14.C Jackisch , G von Minckwitz , H Eidtmann , Dose-dense biweekly doxorubicin/docetaxel versus sequential neoadjuvant chemotherapy with doxorubicin/cyclophosphamide/docetaxel in operable breast cancer: Second interim analysis. Clin Breast Cancer. 2002;3:276280.

15.M Krzyzanowska , M Pintilie . Tannock I. Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA. 2003;290:495501.

19.M Martin , T Pienkowski , J Mackey , Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:23022313.

20.J McIntyre , M Moral , J Bozzo . Combination therapy with valproic acid in cancer: Initial clinical approach. Drugs Fut. 2007;32:4550.

22.D Moher . Reporting research results: A moral obligation for all researchers. Can J Anesth. 2007;54:331335.

24.VM Montori , PJ Devereaux , NKJ Adhikari , Randomized trials stopped early for benefit: A systematic review. JAMA. 2005;294:22032209.

26.J O'Shaughnessy . Developments in the systemic therapy of early-stage breast cancer. Eur J Cancer Suppl. 2007;5:310.

30.MJ Piccart-Gebhart , M Procter , B Leyland-Jones , Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353:16591672.

32.CI Sartor , BL Peterson , S Woolf , Effect of addition of adjuvant paclitaxel on radiotherapy delivery and locoregional control of node-positive breast cancer: Cancer and leukemia group B 9344. J Clin Oncol. 2005;23:57.

33.R Scherer , P Langenberg . von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev. 2007;2.

34.D Schrag . The price tag on progress – chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317319.

37. D Slamon , W Eiermann , N Robert , Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC (R) T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC (R) TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat. 2005;94:S5.

39.I Smith , M Procter , RD Gelber , 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet. 2007;369:2936.

44.F Trotta , G Apolone , S Garattini , Stopping a trial early in oncology: For patients or for industry? Ann Oncol. 2008;19:13471353.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *